The Drug Advisory Committee was established in 2007 to guide WSIB on which drugs to include in our drug benefit plan as well as the medical conditions and criteria needed for coverage. Since 2007, the committee has provided drug recommendations currently part of our plan.
As of 2024, the Drug Advisory Committee has been reconstituted to include therapeutics and is now the Drug and Therapeutics Advisory Committee. The Drug and Therapeutics Advisory Committee provides evidence-based recommendations on drugs and therapeutics, based on benefits, value, safety and includes criteria for coverage.
The experts who serve on the committee are:
Drug and Therapeutics Advisory Committee Members
Dr. Andrea Furlan, MD, PhD (Chair)
Physician, Rehabilitation Pain Services of Toronto Rehab, UHN
Senior Scientist, KITE Institute
Scientist, Institute for Work & Health
Professor, Division of Physical Medicine and Rehabilitation, Temerty Faculty of Medicine, University of Toronto.
Wilfred Steer, BScPhm, MBA (Vice-Chair)
Community Pharmacist
Board Member, Ontario College of Pharmacists
Mina Tadrous, PharmD, MS, PhD
Assistant professor, Leslie Dan Faculty of Pharmacy at the University of Toronto
Scientist, WCH, WIHV Fellow, co-director with the Ontario Drug Policy Research Network
Adjunct Scientist, ICES
Kednapa Thavorn, MPharm, PhD
Senior Scientist and a Scientific Lead of Health Economics, Ottawa Hospital Research Institute
Associate Professor, School of Epidemiology and Public Health, University of Ottawa
Adjunct Scientist, ICES
Dr. Graham Briscoe, MD, MBA, CCFP (SEM) (EM), Dip. Sport Med
Physician, Emergency Medicine
Medical Director, Woodstock Hospital OHAP Program
Assistant Professor, Western University in the Department of Family Medicine
Program Director, Western University’s Sport and Exercise Medicine Fellowship Program, Fowler Kennedy Sport Medicine Clinic
Sandeep Kakan, MSc, FLMI, CEBS, MEM (Public Member)
Director of Pension Governance, Unifor
Board Secretary and Trustee, CWIPP